Dr Darmon received her Ph.D from Université Denis Diderot in Paris in 1990, after undergraduate training in Ecole Normale Supérieure (Cachan), and a master degree at Pasteur Institute. Her research focuses on the molecular biology of the serotoninergic system. During her Ph.D, in CNRS at Gif-sur-Yvette, she identified the gene encoding tryptophan hydroxylase, the enzyme that controls the synthesis of serotonin and joined INSERM as a permanent investigator in 1988. Then, she investigated the molecular bases for the targeting of serotonin receptors in neurons, and received her HDR from Université Denis Diderot. She is now a team leader in the Center for Psychiatry and Neuroscience (Paris). Her team (Cellular biology and molecular pharmacology of central receptors ) is involved in the molecular mechanisms of receptor trafficking, targeting and localization.
The aim of the team is to characterize new pharmaceutical in the field of neurodegenerative diseases and psychiatry. Our approach relies on the observation that neurons are highly polarized cells with many compartments dendrites, dendritic spines, axons and soma. The localization of a receptor in a specialized compartment of the neuron conditions its function and its interaction with intracellular transducing pathways.
The project of the team consists in the characterization of the  mechanisms implicated in the traffic of neuronal receptors. The project  is centered on the mechanisms of receptor traffic (i) during their  targeting to their appropriate localization in neurons [1, 2] and (ii)  after acute or chronic stimulation by a ligand, as well as the  functional consequences on receptor coupling. Our main topic is focused  on the mechanisms of receptor trafficking with a particular interest for  histaminergic and serotoninergic receptors that have been particularly  studied by the members of the team. These receptors are implicated in  the mode of action of several psycho-active drugs used in clinics and  play a role in neuronal and psychiatric pathologies, such as depression  and schizophrenia.  	
 One part of the project explores the adaptative mechanisms that take  place in neurons after a prolonged treatment, notably with the effect of  antidepressant treatment on the desensitization and internalization of  the serotonin 5-HT1A receptor [3]. We also currently investigate the  role of Yif1B, a partner of the 5-HT1A receptor implicated in its  dendritic localization [4, 5]. In particular we analyze the phenotype of  a Yif1B KO mouse that we generated with regards of anxiety and  depression behavioural tests. One hypothesis we made studying the  traffic of the 5-HT1B receptor [6] is that pharmaco-resistance may  result from a mislocalization of a receptor and/or a miscoupling after a  chronic treatment, which could explain the loss of response to a drug.
 In addition the team explores the mechanisms of targeting of other  receptors: serotonin 5-HT3A and 5-HT3B [7], Histamine H3 short or long  isoform [8, 9] and the orphan receptor GPR88 [10], which all present  some particularities of targeting.
 This project will help develop new paradigms in the field of adaptative  mechanisms occurring after prolonged pharmacological treatments and the  development of pharmaco-resistance.
Selected references of the team
